Trial Profile

A Multi-Center, Open Label, Collaborative Research Study to Treat HRS-AKI Patients With Continuous Terlipressin Infusion

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Terlipressin (Primary) ; Midodrine; Norepinephrine; Octreotide
Indications Hepatorenal syndrome
Focus Therapeutic Use
Acronyms INFUSE

Most Recent Events

15 Jul 2024 Status changed from active, no longer recruiting to completed.
29 Dec 2023 New trial record
14 Nov 2023 Results of Comparative Prospective and Retrospective Cohort assessing Efficacy of Continuous Terlipressin Infusion, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com